Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06TNL
|
|||
| Former ID |
DAP000748
|
|||
| Drug Name |
Ethacrynic acid
|
|||
| Synonyms |
Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | High blood pressure [ICD-11: BA00; ICD-10: I10; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Diuretics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H12Cl2O4
|
|||
| Canonical SMILES |
CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
|
|||
| InChI |
1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
|
|||
| InChIKey |
AVOLMBLBETYQHX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 58-54-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
122995, 491575, 798369, 834701, 855762, 5208062, 7847379, 7887267, 8149337, 8152080, 10321631, 11112144, 11336075, 11361314, 11363707, 11366269, 11368831, 11371330, 11374346, 11376993, 11446250, 11462286, 11466287, 11467407, 11483790, 11486033, 11487913, 11490241, 11492359, 11494627, 14776240, 17389016, 24894577, 26611737, 26680116, 26706137, 26746983, 26746984, 29222417, 46392033, 46394202, 46507562, 47662347, 47736552, 47959820, 47959821, 47959822, 48110508, 48185057, 48423385
|
|||
| ChEBI ID |
CHEBI:4876
|
|||
| ADReCS Drug ID | BADD_D00839 ; BADD_D00840 | |||
| SuperDrug ATC ID |
C03CC01
|
|||
| SuperDrug CAS ID |
cas=000058548
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Reaction | Reduction | |||
| Experimental Method | High-throughput screening | |||
| Description | Ethacrynic acid can be metabolized by gut microbiota through reduction. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Ethacrynic acid (adjusted p-values: 8.70E-04). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Ethacrynic acid (adjusted p-values: 6.83E-04). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Ethacrynic acid (adjusted p-values: 2.40E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Ethacrynic acid (adjusted p-values: 3.73E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Ethacrynic acid (adjusted p-values: 1.64E-03). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Ethacrynic acid (adjusted p-values: 5.56E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 12 member 1 (SLC12A1) | Target Info | Blocker | [5], [6] |
| KEGG Pathway | Salivary secretion | |||
| Pancreatic secretion | ||||
| Vibrio cholerae infection | ||||
| Pathwhiz Pathway | Kidney Function | |||
| Reactome | Cation-coupled Chloride cotransporters | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7179). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016092. | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74. | |||
| REF 6 | Inhibition of Na-K-2Cl cotransport and bumetanide binding by ethacrynic acid, its analogues, and adducts. Am J Physiol. 1993 May;264(5 Pt 1):C1270-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.